ArticleDiscover oncology2026
Construction and validation of a prognostic nomogram for advanced esophageal squamous cell carcinoma patients treated with PD-1 inhibitor-based therapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop a prognostic nomogram to enhance the accuracy of survival prediction and guide individualized treatment decisions for patients with advanced esophageal squamous cell carcinoma (ESCC). A total of 162 patients with advanced ESCC treated with PD-1 inhibitor-based therapy at the First Affiliated Hospital of Anhui Medical University constituted the training set, while 79 patients from the Second Affiliated Hospital formed the validation set. Independent prognostic factors associated with overall survival (OS) were identified using multivariate Cox regression analysis to construct the nomogram. The model’s performance was evaluated in terms of discrimination, calibration, generalizability and clinical utility through the concordance index (C-index), area under the receiver operating characteristic curve (AUC), calibration plots, external validation and decision curve analysis (DCA). Kaplan-Meier analysis with Log-Rank tests was employed to compare OS across different risk strata. The nomogram incorporated five independent prognostic variables. In the training set, the C-index was 0.769, with AUC values of 0.942, 0.850, and 0.658 for predicting 0.5-, 1-, and 2-year OS, respectively. In the validation set, the C-index was 0.786, with corresponding AUC values of 0.916, 0.919, and 0.800. The nomogram demonstrated superior predictive performance compared to the neutrophil-to-lymphocyte ratio (NLR) based on both C-index and AUC metrics. Calibration plots showed good agreement between predicted and observed survival probabilities at 0.5, 1, and 2 years. DCA confirmed the satisfactory clinical utility of the model. Stratification analyses revealed significantly longer OS in low-risk patients compared to high-risk patients in both sets (all P < 0.001). This nomogram provides a reliable tool for predicting prognosis in patients with advanced ESCC undergoing PD-1 inhibitor-based therapy, offering a potential reference for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.